Inclisiran: First Approval.
Drugs
; 81(3): 389-395, 2021 Feb.
Article
in English
| MEDLINE | ID: covidwho-1130968
ABSTRACT
Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet. It is intended for use in combination with a statin or a statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol goals with the maximum tolerated statin dose. In patients who are statin-intolerant or for whom a statin is contraindicated, inclisiran can be used alone or in combination with other lipid-lowering therapies. Inclisiran is administered as a twice-yearly subcutaneous injection. This article summarizes the milestones in the development of inclisiran leading to this first approval for primary hypercholesterolaemia or mixed dyslipidaemia.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
RNA, Small Interfering
/
Dyslipidemias
/
Hypercholesterolemia
/
Anticholesteremic Agents
Limits:
Humans
Language:
English
Journal:
Drugs
Year:
2021
Document Type:
Article
Affiliation country:
S40265-021-01473-6
Similar
MEDLINE
...
LILACS
LIS